Recombinant, ETA′-based CD64 immunotoxins: Improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice

British Journal of Dermatology

Volumn 163, Issue 2, 2010, Pages 279-286

  Ribbert, T ^a   Thepen, T ^a   Tur, M K ^b   Fischer, R ^a   Huhn, M ^c   Barth, S ^a,b  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

activated macrophages; CD64; inflammation; periplasmic expression; recombinant immunotoxin; single chain Fv

Indexed keywords

HYBRID PROTEIN; MONOCLONAL ANTIBODY H22 EXOTOXIN A; UNCLASSIFIED DRUG; EXOTOXIN; FC RECEPTOR; IMMUNOGLOBULIN FRAGMENT; IMMUNOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG PURIFICATION; FERMENTATION TECHNIQUE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INFLAMMATION; ANIMAL; CHEMISTRY; CHRONIC DISEASE; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; PATHOPHYSIOLOGY; SKIN DISEASE; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; EXOTOXINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INFLAMMATION; MACROPHAGES; MICE; MICE, TRANSGENIC; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SKIN DISEASES;

EID: 77954877326     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09824.x     Document Type: Article

References (35)

1. Blom AB, van Lent PL, van Vuuren H et al. Fc gamma R expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA). Arthritis Res 2000 2 : 489 503.
2. van Vuuren AJ, van Roon JA, Walraven V et al. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J Immunol 2006 176 : 5833 5838.
3. van Roon JA, van Vuuren AJ, Wijngaarden S et al. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. Arthritis Rheum 2003 48 : 1229 1238.
4. van Roon JA, Bijlsma JW, van de Winkel JG et al. Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate. Ann Rheum Dis 2005 64 : 865 870.
5. Wang H, Peters T, Kess D et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006 116 : 2105 2114.
6. Kiekens RC, Thepen T, Bihari IC et al. Expression of Fc receptors for IgG during acute and chronic cutaneous inflammation in atopic dermatitis. Br J Dermatol 2000 142 : 1106 1113.
7. Leslie RGQ. Macrophage handling of soluble immune complexes. Immunol Today 1980 1 : 78 84.
8. Silverstein SC, Steinman RM, Cohn ZA. Endocytosis. Annu Rev Biochem 1977 46 : 669 722.
9. Unkeless JC, Fleit H, Mellman IS. Structural aspects and heterogeneity of immunoglobulin Fc receptors. Adv Immunol 1981 31 : 247 270.
10. Thepen T, van Vuuren AJ, Kiekens RC et al. Resolution of cutaneous inflammation after local elimination of macrophages. Nat Biotechnol 2000 18 : 48 51.
11. Zhong RK, van de Winkel JG, Thepen T et al. Cytotoxicity of anti-CD64-ricin A chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. J Hematother Stem Cell Res 2001 10 : 95 105.
12. Leemans JC, Thepen T, Weijer S et al. Macrophages play a dual role during pulmonary tuberculosis in mice. J Infect Dis 2005 191 : 65 74.
13. Colcher D, Pavlinkova G, Beresford G et al. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998 42 : 225 241.
14. Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 1998 16 : 513 520.
15. Byers VS, Baldwin RW. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology 1988 65 : 329 335.
16. Tur MK, Sasse S, Stocker M et al. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int J Mol Med 2001 8 : 579 584.
17. Barth S, Huhn M, Matthey B et al. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000 95 : 3909 3914.
18. Bruell D, Stocker M, Huhn M et al. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA′ suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 2003 23 : 1179 1186.
19. Bruell D, Bruns CJ, Yezhelyev M et al. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA′ demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 2005 15 : 305 313.
20. Tur MK, Huhn M, Thepen T et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 2003 63 : 8414 8419.
21. Huhn M, Sasse S, Tur MK et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001 61 : 8737 8742. (Pubitemid 34013885)
22. Laskin DL, Pendino KJ. Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol 1995 35 : 655 677.
23. Pastan I, Hassan R, FitzGerald DJ et al. Immunotoxin treatment of cancer. Annu Rev Med 2007 58 : 221 237.
24. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003 52 : 338 341.
25. Barth S, Huhn M, Matthey B et al. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 2000 66 : 1572 1579.
26. Hetzel C, Bachran C, Fischer R et al. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells. J Immunother 2008 31 : 370 376.
27. Wallace PK, Keler T, Coleman K et al. Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcgammaRI), blocks phagocytosis, and modulates receptor expression. J Leukoc Biol 1997 62 : 469 479.
28. Du X, Beers R, Fitzgerald DJ et al. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 2008 68 : 6300 6305.
29. Bera TK, Williams-Gould J, Beers R et al. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer. Mol Cancer Ther 2001 1 : 79 84.
30. Bera TK, Viner J, Brinkmann E et al. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res 1999 59 : 4018 4022.
31. Chen KC, Kim J, Li X et al. Modeling recombinant immunotoxin efficacies in solid tumors. Ann Biomed Eng 2008 36 : 486 512.
32. Vitetta ES. Immunotoxins and vascular leak syndrome. Cancer J 2000 6 (Suppl. 3 S218 24.
33. Baluna R, Coleman E, Jones C et al. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res 2000 258 : 417 424.
34. Pastan I, Hassan R, Fitzgerald DJ et al. Immunotoxin therapy of cancer. Nat Rev Cancer 2006 6 : 559 565.
35. Stahnke B, Thepen T, Stocker M et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008 7 : 2924 2932.